Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine.
M2 PHARMA-August 31, 2018-Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
(C)2018 M2 COMMUNICATIONS
- Pivotal data from the Phase III HAVEN 3 study, which evaluated Hemlibra (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors, were published in the 30 August, issue of the New England Journal of Medicine (NEJM), US-based biotechnology company Genentech said.
Genentech is a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY).
Data from the HAVEN 3 study showed that Hemlibra prophylaxis administered subcutaneously every week or every two weeks significantly reduced treated bleeds by 96% (rate ratio [RR]=0.04; p
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 31, 2018|
|Previous Article:||Vertex, Genomics Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines.|
|Next Article:||Gene Therapy Specialist ReflectionBio Receives Orphan Drug Designation from US FDA for the Treatment of Bietti's Crystalline Dystrophy.|